In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

Furie et al. now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal antibody against B-lymphocyte stimulator—which both stimulates ...